GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Upper GI Tract/Psychological Factors Shape Outcomes After Achalasia Treatment- Gastroenterology Feb.26

Psychological Factors Shape Outcomes After Achalasia Treatment- Gastroenterology Feb.26

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated February 1, 2026

Quick Answer

Introduction Achalasia is traditionally managed as a pure motility disorder, and treatment success is usually judged by technical outcomes—lower oesophageal sphincter (LES) disruption, improved emptying on timed barium esophagram (TBE), and manometric changes. Yet, many clinicians recognise a frustrating reality: Some patients continue to report dysphagia, chest pain, and poor quality of life despite objectively successful treatment.


Introduction

Achalasia is traditionally managed as a pure motility disorder, and treatment success is usually judged by technical outcomes—lower oesophageal sphincter (LES) disruption, improved emptying on timed barium esophagram (TBE), and manometric changes. Yet, many clinicians recognise a frustrating reality:

Some patients continue to report dysphagia, chest pain, and poor quality of life despite objectively successful treatment.

This study addresses an often-overlooked question:

Do psychological factors—specifically oesophageal hypervigilance and anxiety—predict how patients feel after achalasia treatment?

The clinical problem

Persistent symptoms after pneumatic dilation, POEM, or Heller myotomy are commonly attributed to:

incomplete myotomy,

reflux, or

residual obstruction.

However, these explanations do not fully account for patients who have:

good oesophageal emptying,

acceptable manometry, and

no major structural issues—yet remain highly symptomatic.

This raises the possibility that central symptom processing, not oesophageal mechanics alone, influences outcomes.

What the authors studied:

The investigators evaluated achalasia patients after definitive therapy and assessed:

Oesophageal Hypervigilance and Anxiety using the EHAS (a validated scale),

Oesophageal-specific quality of life (E-QOL / NEQOL),

Objective measures such as TBE.

They then examined whether psychological measures predicted post-treatment symptoms and quality of life independent of objective oesophageal findings.

Key findings clinicians should understand

1) Hypervigilance and anxiety strongly predict patient-reported outcomes

Higher scores on oesophageal hypervigilance and anxiety were associated with:

worse post-treatment symptoms, and

poorer oesophageal-specific quality of life.

This relationship persisted even when objective measures were acceptable.

2) Objective success does not guarantee symptomatic success

Patients with good TBE results and technically successful interventions still reported poor outcomes if hypervigilance and anxiety were high.

3) Achalasia outcomes are not purely mechanical

These findings support a brain–esophagus interaction, where heightened symptom monitoring, fear of symptoms, and anxiety amplify symptom perception after treatment.

Why this matters in clinical practice

Explains “unexplained failure”

This study helps explain why some patients remain dissatisfied after technically successful achalasia therapy.

Pre-treatment counseling

Identifying high hypervigilance/anxiety before intervention may:

set realistic expectations,

reduce post-treatment dissatisfaction.

Post-treatment management

Persistent symptoms should not automatically trigger:

repeat dilation,

redo POEM,

or escalation to surgery.

In selected patients, psychological or behavioural interventions may be more appropriate.

Practical take-home messages

If post-treatment symptoms do not match objective findings, consider hypervigilance and anxiety.

Use validated tools (like EHAS) to identify at-risk patients.

A multidisciplinary approach—including behavioural therapy, reassurance, and symptom education—may improve outcomes more than additional procedures.

Bottom-line takeaway:

In achalasia, patient outcomes are driven not only by oesophagal emptying, but also by how symptoms are perceived and processed. Addressing oesophagal hypervigilance and anxiety is essential to improving real-world treatment success.

One-line GastroAGI takeaway

Successful achalasia treatment requires treating both the esophagus and the brain.

Related Q&A

Basal Crypt Dysplasia in Barrett's Esophagus: GUT | July 2026

Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...

High-Resolution Impedance Manometry after POEM: AJG | May 2026

Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...

Magnetic Sphincter Augmentation Provides Durable GERD Control : Ann Surg | Jun 2026

Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...

New Strategies Needed for Resistant H. pylori : Indian J Gastroenterol | Jun 2026

Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...

Vonoprazan–Tetracycline Dual Therapy Simplifies H. pylori Rescue Treatment : Gastroenterology | June 2026

Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...

H. pylori Eradication Reduces Cancer but Mortality Benefit Remains Fragile : Gastroenterology | June 2026

Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer